Return to LTBI Slide Set Main Menu
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,
2005
Slide 1: Targeted
Tuberculin Testing and Treatment of Latent Tuberculosis Infection, 2005
Applying CDC/ATS Guidelines in Your Clinical Practice
Division of Tuberculosis Elimination
Centers for Disease Control and Prevention
Back to LTBI Slide Set Main Menu
Slide 2: Targeted Tuberculin
Testing and Treatment of Latent Tuberculosis Infection
As tuberculosis (TB) disease rates in the United States (U.S.) decrease,
finding and treating persons at high risk for latent TB infection (LTBI)
has become a priority.
Back to LTBI Slide Set Main Menu
Slide 3: Latent TB
Infection (LTBI)
LTBI is the presence of M. tuberculosis organisms (tubercle bacilli)
without symptoms or radiographic evidence of TB disease.
Back to LTBI Slide Set Main Menu
Slide 4: Terminology
Slide 5: LTBI vs. Pulmonary TB Disease
Latent TB Infection
- TST* or QFT† positive
- Negative chest radiograph
- No symptoms or physical findings suggestive of TB disease
Pulmonary TB Disease
- TST or QFT usually positive
- Chest radiograph may be abnormal
- Symptoms may include one or more of the following: fever, cough,
night sweats, weight loss, fatigue, hemoptysis, decreased appetite
- Respiratory specimens may be smear or culture positive
* tuberculin skin test
† QFT (QuantiFERON-TB and QuantiFERON-Gold) is a blood test
to detect M. tuberculosis infection.
Back to LTBI Slide Set Main Menu
Slide 6: Targeted Tuberculin Testing
Slide 7: Treatment of LTBI – Milestones
(1)
For more than 3 decades, an essential component of TB prevention and
control in the U.S. has been the treatment of persons with LTBI to prevent
TB disease.
Back to LTBI Slide Set Main Menu
Slide 8: Treatment of LTBI – Milestones
(2)
1965: American Thoracic Society (ATS) recommends treatment of LTBI for
those with previously untreated TB, tuberculin skin test (TST) converters,
and young children.
1967: Recommendations expanded to include all TST positive reactors (>
10 mm).
Back to LTBI Slide Set Main Menu
Slide 9: Treatment of LTBI – Milestones
(3)
1974: CDC and ATS guidelines established for pretreatment screening to
decrease risk of hepatitis associated with treatment
- Treatment recommended for persons < 35 years of
age
Back to LTBI Slide Set Main Menu
Slide 10: Treatment of LTBI
– Milestones (4)
1983: CDC recommends clinical and laboratory monitoring of persons >
35 who require treatment for LTBI
1998: CDC recommends 2 months of rifampin (RIF) plus pyrazinamide (PZA)
as an option for HIV-infected patients (later changed)
Back to LTBI Slide Set Main Menu
Slide 11: Treatment of LTBI – Milestones
(5)
2000: CDC and ATS issue updated guidelines for targeted testing and LTBI
treatment1
- 9-month regimen of isoniazid (INH) is preferred
- 2-month regimen of RIF and PZA and a 4-month regimen of RIF recommended
as options (later changed)
1 MMWR June 9, 2000; 49(No. RR-6)
Back to LTBI Slide Set Main Menu
Slide 12: Treatment of LTBI – Milestones
(6)
2001: Owing to liver injury and death associated with 2-month regimen
of RIF and PZA, use of this option de-emphasized in favor of other regimens2
2003: 2-month regimen of RIZ and PZA generally not recommended — to be
used only if the potential benefits outweigh the risk of severe liver
injury and death3
2 MMWR August 31, 2001; 50(34): 733-735
3 MMWR August 8, 2003; 52(31): 735-739
Back to LTBI Slide Set Main Menu
Slide 13: What’s New (1)
Tuberculin skin testing
- Emphasis on targeting persons at high risk
- 5-mm induration cutoff level for organ transplant recipients
and other immunosuppressed patients being treated with prednisone or
TNF-a antagonists4
- Skin-test conversion defined as increase of > 10
mm of induration within a 2-year period, regardless of age
4 MMWR August 61, 2004; 53(33): 683-686
Back to LTBI Slide Set Main Menu
Slide 14: What’s New (2)
Treatment of LTBI
- HIV-negative persons – INH for 9 months preferred regimen
- HIV-positive persons and those with fibrotic lesions on chest x-ray
(consistent with previous TB) – INH should be given for 9 months
- For all persons – RIF for 4 months is an option
Back to LTBI Slide Set Main Menu
Slide 15: What’s New (3)
Clinical and laboratory monitoring
- Routine baseline and follow-up monitoring not required except for
- HIV-infected persons
- Pregnant women or those in early postpartum period
- Persons with chronic liver disease or who use alcohol regularly
- Monthly monitoring for signs or symptoms of possible adverse effects
Back to LTBI Slide Set Main Menu
Slide 16: Identifying Risk
Factors That Lead to Development of TB Disease
Back to LTBI Slide Set Main Menu
Slide 17: Persons at Risk for Developing
TB Disease
Persons at high risk for developing TB disease fall into 2 categories
- Those who have been recently infected
- Those with clinical conditions that increase their risk of progressing
from LTBI to TB disease
Back to LTBI Slide Set Main Menu
Slide 18: Recent
Infection as a Risk Factor (1)
Persons more likely to have been recently infected include
- Close contacts to person with infectious TB
- Skin test converters (within past 2 years)
- Recent immigrants from TB-endemic regions of the world (within 5
years of arrival to the U.S.)
Back to LTBI Slide Set Main Menu
Slide 19:
Recent Infection as a Risk
Factor (2)
- Children < 5 years with a positive TST
- Residents and employees of high-risk congregate settings (e.g., correctional
facilities, homeless shelters, health care facilities)
Back to LTBI Slide Set Main Menu
Slide 20: Increased Risk for Progression
to TB Disease (1)
Persons more likely to progress from LTBI to TB disease include
- HIV-infected persons
- Those with a history of prior, untreated TB or fibrotic lesions on
chest radiograph
Back to LTBI Slide Set Main Menu
Slide 21: Increased Risk for Progression
to TB Disease (2)
- Underweight or malnourished persons
- Injection drug users
- Those receiving TNF-a antagonists for treatment
of rheumatoid arthritis or Crohn’s disease
Back to LTBI Slide Set Main Menu
Slide 22: Increased Risk for Progression
to TB Disease (3)
- Persons with certain medical conditions such as
- Silicosis
- Diabetes mellitus
- Chronic renal failure or on hemodialysis
- Solid organ transplantation (e.g., heart, kidney)
- Carcinoma of head or neck
- Gastrectomy or jejunoilial bypass
Back to LTBI Slide Set Main Menu
Slide 23: Tuberculin Testing
Back to LTBI Slide Set Main Menu
Slide 24: Testing
for M. tuberculosis Infection
Mantoux tuberculin skin test (TST)
- Skin test that produces delayed-type hypersensitivity reaction in
persons with M. tuberculosis infection
QuantiFERON® -TB test and QuantiFERON® - Gold
- Blood test that measures and compares amount of interferon-gamma (IFN-g)
released by blood cells in response to antigens
Back to LTBI Slide Set Main Menu
Slide 25: Mantoux Tuberculin Skin
Test
- Preferred method of skin testing for M. tuberculosis infection
- TST is useful for
- Determining how many people in a group are infected (e.g., contact
investigation)
- Examining persons who have symptoms of TB
- Multiple puncture tests (e.g., Tine Test) are inaccurate and not
recommended
Back to LTBI Slide Set Main Menu
Slide 26: Administering the
TST
- Inject 0.1 ml of 5 TU PPD tuberculin solution intradermally on volar
surface of lower arm using a 27-gauge needle
- Produce a wheal 6 to 10 mm in diameter
Back to LTBI Slide Set Main Menu
Slide 27: Reading the TST (1)
- Measure reaction in 48 to 72 hours
- Measure induration, not erythema
- Record reaction in millimeters, not “negative” or “positive”
- Ensure trained health care professional measures and interprets the
TST
Back to LTBI Slide Set Main Menu
Slide 28: Reading the TST (2)
- Educate patient and family regarding significance of a positive TST
result
- Positive TST reactions can be measured accurately for up to 7 days
- Negative reactions can be read accurately for only 72 hours
Back to LTBI Slide Set Main Menu
Slide 29: TST Interpretation (1)
5-mm induration is interpreted as positive in
- HIV-infected persons
- Close contacts to an infectious TB case
- Persons with chest radiographs consistent with prior untreated TB
Back to LTBI Slide Set Main Menu
Slide 30: TST Interpretation (2)
5-mm induration is interpreted as positive in (cont.)
- Organ transplant recipients
- Other immunosuppressed patients (e.g., those taking the equivalent
of >15 mg/d of prednisone for 1 month or those taking TNF-a
antagonists)
Back to LTBI Slide Set Main Menu
Slide 31: TST Interpretation (3)
10-mm induration is interpreted as positive in
- Recent immigrants
- Injection drug users
- Residents or employees of congregate settings
- Mycobacteriology laboratory personnel
Back to LTBI Slide Set Main Menu
Slide 32: TST Interpretation (4)
10-mm induration is interpreted as positive in (cont.)
- Persons with clinical conditions that place them at high risk
- Children < 4 years; infants, children, and adolescents exposed
to adults at high-risk
Back to LTBI Slide Set Main Menu
Slide 33: TST Interpretation (5)
15-mm induration is interpreted as positive in
- Persons with no known risk factors for TB.*
*Although skin testing programs should be conducted only among high-risk
groups, certain individuals may require TST for employment or school attendance.
Diagnosis and treatment of LTBI should always be tied to risk assessment.
Back to LTBI Slide Set Main Menu
Slide 34: Factors That May
Cause False-Positive TST Reactions
- Nontuberculous mycobacteria
- Reactions caused by nontuberculous mycobacteria are usually
< 10 mm of induration
- BCG vaccination
- Reactivity in BCG vaccine recipients generally wanes over time;
positive TST result is likely due to TB infection if risk factors
are present
Back to LTBI Slide Set Main Menu
Slide 35: Factors That May
Cause False-Negative TST Reactions (1)
- Anergy
- Inability to react to a TST because of a weakened immune system
- Usefulness of anergy testing in TST-negative persons who are HIV
infected has not been demonstrated
Back to LTBI Slide Set Main Menu
Slide 36: Factors That May
Cause False-Negative TST Reactions (2)
- Recent TB infection
- Defined as 2 to 10 weeks after exposure
- Very young age
Back to LTBI Slide Set Main Menu
Slide 37: Factors That May Cause False-Negative
TST Reactions (3)
- Live-virus vaccination
- For example, measles or smallpox
- Can temporarily suppress TST reactivity
- Overwhelming TB disease
- Poor TST administration technique
- For example, TST injection too shallow or too deep, or wheal
is too small
Back to LTBI Slide Set Main Menu
Slide 38: Boosting
- Some people with LTBI may have a negative skin test reaction when
tested years after infection because of a waning response.
- An initial skin test may stimulate (boost) the ability to react to
tuberculin.
- Positive reactions to subsequent tests may be misinterpreted as new
infections rather than “boosted” reactions.
Back to LTBI Slide Set Main Menu
Slide 39: Two-Step Testing (1)
- A strategy to determine the difference between boosted reactions
and reactions due to recent infection.
- If first TST is positive, consider the person infected
- If first TST is negative, give second TST 1–3 weeks later
- If second TST is positive, consider the person infected
- If second TST is negative, consider the person uninfected at
baseline
Back to LTBI Slide Set Main Menu
Slide 40: Two-Step Testing
(2)
- Use two-step tests for initial baseline skin testing of adults who
will be retested periodically (e.g., health care workers).
Back to LTBI Slide Set Main Menu
Slide 41: QuantiFERON®-TB
Test and QuantiFERON®-Gold Test (1)
- Whole-blood test used to detect M. tuberculosis infection
- Approved by the U.S. Food and Drug Administration (FDA)
- Entails mixing blood samples with antigens from M. tuberculosis,
M. avium complex, and controls and incubating for 16 to 24 hours
Back to LTBI Slide Set Main Menu
Slide 42: QuantiFERON®-TB
Test and QuantiFERON®-Gold Test (2)
- Cells that recognize the antigen release interferon-g
- Amount of interferon released in response to tuberculin is compared
to amount released in response to other antigens5
5 MMWR January 31,2003; 52 (RR-02): 15-18 and CDC
Fact Sheet Document # 250103, March 2003
Back to LTBI Slide Set Main Menu
Slide 43: LTBI Treatment Regimens
Back to LTBI Slide Set Main Menu
Slide 44: Initiating
Treatment
Before initiating treatment for LTBI
- Rule out TB disease (i.e., wait for culture result if specimen obtained)
- Determine prior history of treatment for LTBI or TB disease
- Assess risks and benefits of treatment
- Determine current and previous drug therapy
Back to LTBI Slide Set Main Menu
Slide 45: Isoniazid Regimens (1)
- 9-month regimen of isoniazid (INH) is the preferred regimen
- 6-month regimen is less effective but may be used if unable to complete
9 months
- May be given daily or intermittently (twice weekly)
- Use directly observed therapy (DOT) for intermittent regimen
Back to LTBI Slide Set Main Menu
Slide 46: Isoniazid Regimens (2)
- INH daily for 9 months
(270 doses within 12 months)
- INH twice/week for 9 months
(76 doses within 12 months)
- INH daily for 6 months
(180 doses within 9 months)
- INH twice/week for 6 months
(52 doses within 9 months)
Back to LTBI Slide Set Main Menu
Slide 47: Rifampin Regimens (1)
- Rifampin (RIF) given daily for 4 months is an acceptable alternative
when treatment with INH is not feasible.
- In situations where RIF cannot be used (e.g., HIV-infected persons
receiving protease inhibitors), rifabutin may be substituted.
Back to LTBI Slide Set Main
Menu
Slide 48: Rifampin Regimens (2)
- RIF daily for 4 months
(120 doses within 6 months)
- RIF and PZA for 2 months should generally not be offered due to risk
of severe adverse events6
6 MMWR August 8, 2003; 52 (31): 735-739
Back to LTBI Slide Set Main
Menu
Slide 49: Completion of Therapy
Completion of therapy is based on the total number of doses administered,
not on duration alone.
Back to LTBI Slide Set Main
Menu
Slide 50: Management of Patient Who Missed Doses
- Extend or re-start treatment if interruptions were frequent or prolonged
enough to preclude completion
- When treatment has been interrupted for more than 2 months, patient
should be examined to rule out TB disease
- Recommend and arrange for DOT as needed
Back to LTBI Slide Set Main
Menu
Slide 51: Monitoring During Treatment
Back to LTBI Slide Set Main
Menu
Slide 52: Clinical Monitoring (1)
Instruct patient to report signs or symptoms of adverse drug reactions
- Rash
- Anorexia, nausea, vomiting, or abdominal pain in right upper quadrant
- Fatigue or weakness
- Dark urine
- Persistent numbness in hands or feet
Back to LTBI Slide Set Main
Menu
Slide 53: Clinical Monitoring (2)
Monthly visits should include a brief physical exam and a review of
- Rationale for treatment
- Adherence with therapy
- Symptoms of adverse drug reactions
- Plans to continue treatment
Back to LTBI Slide Set Main Menu
Slide 54: Clinical Monitoring (3)
- Incidence of hepatitis in persons taking INH is lower than previously
thought (0.1 to 0.15%)
- Hepatitis risk increases with age
- Uncommon in persons < 20 years old
- Nearly 2% in persons 50 to 64 years old
- Risk increased with underlying liver disease or heavy alcohol consumption
Back to LTBI Slide Set Main
Menu
Slide 55: Laboratory Monitoring (1)
Baseline liver function tests (e.g., AST, ALT, and bilirubin) are not
necessary except for patients with the following risk factors:
- HIV infection
- History of liver disease
- Alcoholism
- Pregnancy or in early postpartum period
Back to LTBI Slide Set Main
Menu
Slide 56: Laboratory Monitoring (2)
Repeat laboratory monitoring if patient has
- Abnormal baseline results
- Current or recent pregnancy
- High risk for adverse reactions
- Symptoms of adverse reaction
- Liver enlargement or tenderness during examination
Back to LTBI Slide Set Main
Menu
Slide 57: Laboratory Monitoring (3)
- Asymptomatic elevation of hepatic enzymes seen in 10%-20% of people
taking INH
- Levels usually return to normal after completion of treatment
- Some experts recommend withholding INH if transaminase level exceeds
3 times the upper limit of normal if patient has symptoms of hepatotoxicity,
and 5 times the upper limit of normal if patient is asymptomatic7
7 MMWR June 9, 2000; 49(No. RR-6): 39
Back to LTBI Slide Set Main
Menu
Slide 58: Meeting the Challenge of TB Prevention
For every patient
- Assess TB risk factors
- If risk is present, perform TST or QFT
- If TST or QFT is positive, rule out active TB disease
- If active TB disease is ruled out, initiate treatment for LTBI
- If treatment is initiated, ensure completion
Back to LTBI Slide Set Main
Menu
Slide 59: Additional Resources
For additional information on TB, visit the CDC Division of Tuberculosis
Elimination Website at www.cdc.gov/tb
Back to LTBI Slide Set Main
Menu
Slide 60: Guidelines Available Online
Back to LTBI Slide Set Main
Menu
Slide 61: Case Studies
Back to LTBI Slide Set Main
Menu
Slide 62: Case Study A (1)
Patient history
- 29-year-old African-American female
- History of diabetes
- 35 weeks pregnant
- TST = 20 mm of induration
- No symptoms of TB disease
- CXR, CBC, LFTs normal
- No known contact with TB patient
Back to LTBI Slide Set Main
Menu
Slide 63: Case Study A (2)
Questions
- What are this patient’s risk factors for TB infection or disease?
- What is the appropriate management for this patient?
Back to LTBI Slide Set Main
Menu
Slide 64: Case Study A (3)
Discussion of risk factors
- Persons with diabetes mellitus are 2 to 4 times more likely to develop
TB disease than those without diabetes
- Risk may be higher in insulin-dependent diabetics and those with
poorly controlled diabetes
Back to LTBI Slide Set Main Menu
Slide 65: Case Study A (4)
Discussion of management
- Pregnancy has minimal influence on the pathogenesis of TB or the
likelihood of LTBI progressing to disease
- Pregnant women should be targeted for TB testing only if they have
specific risk factors for LTBI or progression to disease
Back to LTBI Slide Set Main Menu
Slide 66: Case Study A (5)
Discussion of management
- Some experts prefer to delay treatment until after the early postpartum
period, unless the person has recent TB infection or HIV infection
Back to LTBI Slide Set Main Menu
Slide 67: Case Study B (1)
Patient history
- 47-year-old Hispanic male
- Moved to U.S. from Bolivia 4 years ago
- Known contact of infectious TB case
- TST = 5 mm of induration
- 3 months later TST = 23 mm of induration
- No symptoms of TB disease
- Normal CXR, CBC, AST, and bilirubin
Back to LTBI Slide Set Main Menu
Slide 68: Case Study B (2)
Questions
- What are the patient’s risk factors for TB infection or disease?
- Has the management of this patient to date been appropriate?
Back to LTBI Slide Set Main Menu
Slide 69: Case Study B (3)
Discussion of risk factors
- Patient is a contact of an infectious TB case
- Recent immigrant to the U.S. from a country with a high prevalence
of TB
Back to LTBI Slide Set Main Menu
Slide 70: Case Study B (4)
Discussion of risk factors
- If the patient had not been a contact, the recency of his immigration
(less than 4 years) would have made him a candidate for TB testing,
but the 5-mm reaction would not be considered positive
- Persons who immigrate from TB-endemic countries have increased rates
of TB
Back to LTBI Slide Set Main Menu
Slide 71: Case Study B (5)
Discussion of risk factors
- Rates of TB approach those of their countries of origin for 5 years
after arrival in the U.S.
- These increased rates most likely result from recent M. tuberculosis
infection in their native country
Back to LTBI Slide Set Main Menu
Slide 72: Case Study B (6)
Discussion of management
- Should be treated for LTBI if TST reactions > 10
mm of induration
- As a contact of an active TB case, 5 mm of induration is considered
positive
- This patient should have been treated for LTBI immediately after
the first TST
Back to LTBI Slide Set Main Menu
Slide 73: Case Study C (1)
Patient history
- 36-year-old Asian female
- Moved to U.S. from Philippines > 15 years ago
- Plans to work in a correctional facility
- TST result negative 1 year ago
- TST for pre-employment physical = 26 mm of induration
- CXR normal
- No symptoms of TB disease
- No known contact with a TB patient
Back to LTBI Slide Set Main Menu
Slide74: Case Study C (2)
Questions
- What are the patient’s risk factors for TB infection or disease?
- What is the appropriate management for this patient?
Back to LTBI Slide Set Main Menu
Slide 75: Case Study C (3)
Discussion of risk factors
- Patient’s TST converted from negative to positive (within a 2-year
period)
- TST conversion increases risk for progressing from LTBI to TB disease
- Foreign-born status is less of a risk factor, i.e., she immigrated
more than 5 years ago
Back to LTBI Slide Set Main Menu
Slide 76: Case Study C (4)
Discussion of management
- Patient’s TST conversion indicates failure to identify this person
as high risk for recent exposure to TB
- Patient may have had extended travel to her country of origin or
other high-prevalence parts of the world
Back to LTBI Slide Set
Main Menu
Slide 77: Case Study C (5)
Discussion of management
- Patient is a recent converter and, as such, is a candidate for treatment
of LTBI with INH
Back to LTBI Slide Set Main Menu
Last Reviewed: 05/18/2008 Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Back to Top of Page
You will need Adobe Acrobat Reader
v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat Reader.
If you have difficulty accessing any
material on the DTBE Web site because of a disability, please contact
us in writing or via telephone and we will work with you to make the information
available.
Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: tbinfo@cdc.gov
|
Home | Site Map
| Contact Us
Accessibility
| Privacy Policy Notice |
FOIA
| USA.gov
CDC Home |
Search |
Health Topics A-Z
Centers for Disease Control & Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination Please send comments/suggestions/requests to:
CDCINFO@cdc.gov
|